Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
ARDUAN (pipecuronium bromide) is a neuromuscular blocking agent administered by injection used during anesthesia to facilitate intubation and surgical relaxation. It works as a competitive antagonist at the neuromuscular junction, blocking acetylcholine receptors to produce paralysis. This injectable agent is indicated for patients requiring muscle relaxation during general anesthesia and mechanical ventilation.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a contracting team focused on transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ARDUAN offers minimal career development opportunity given zero linked job openings and approaching loss of exclusivity. This product is best suited for professionals seeking a stable, low-intensity role managing a legacy franchise rather than those pursuing growth-focused career trajectories.
Worked on ARDUAN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.